AZD4635: Phase I started

Sosei’s Heptares Therapeutics Ltd. subsidiary said AstraZeneca began an open-label, dose-escalation, U.S. Phase I trial

Read the full 159 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE